Octanoic Acid Suppresses Harmaline-Induced Tremor in Mouse Model of Essential Tremor

Neurotherapeutics

Volumn 9, Issue 3, 2012, Pages 635-638

  Nahab, Fatta B ^a   Handforth, Adrian ^b   Brown, Tyler ^a,e   Shin, Christopher ^b   Quesada, Arnulfo ^c   Dong, Chuanhui ^a   Haubenberger, Dietrich ^d,e   Hallett, Mark ^e  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

1 octanol; Essential tremor; Harmaline; Octanoic acid; Therapeutics

Indexed keywords

HARMALINE; OCTANOIC ACID; OCTANOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ESSENTIAL TREMOR; MALE; MOTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANIMALS; CAPRYLATES; CENTRAL NERVOUS SYSTEM STIMULANTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ESSENTIAL TREMOR; HARMALINE; MALE; MICE; MICE, INBRED ICR;

EID: 84866455117     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-012-0121-1     Document Type: Article

References (16)

1. Elble R, Deuschl G. Milestones in tremor research. Movement Disord 2011; 26: 1096-1105.
2. Paris-Robidas S, Brochu E, Sintes M, et al. Defective dentate nucleus GABA receptors in essential tremor. Brain 2012; 135: 105-116.
3. 11C-flumazenil PET study. J Nucl Med 2010; 51: 1030-1035.
4. Zesiewicz TA, Elble R, Louis ED, et al. Evidence-based guideline update: Treatment of essential tremor: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2011; 77: 1752-1755.
5. Deuschl G, Raethjen J, Hellriegel H, Elble R. Treatment of patients with essential tremor. Lancet Neurol 2011; 10: 148-161.
6. Koller WC, Busenbark K, Miner K. The relationship of essential tremor to other movement disorders: report on 678 patients. Essential Tremor Study Group. Ann Neurol 1994; 35: 717-723.
7. Koller WC, Biary N. Effect of alcohol on tremors: comparison with propranolol. Neurology 1984; 34: 221-222.
8. Llinas R, Yarom Y. Specific blockade of the low threshold calcium channel by high molecular weight alcohols. Soc Neurosci 1986; 12: 174.
9. Llinas R, Yarom Y. Properties and distribution of ionic conductances generating electroresponsiveness of mammalian inferior olivary neurones in vitro. J Physiol 1981; 315: 569-584.
10. Sinton CM, Krosser BI, Walton KD, Llinas RR. The effectiveness of different isomers of octanol as blockers of harmaline induced tremor. Pflugers Arch 1989; 414: 3136.
11. Bushara KO, Goldstein SR, Grimes GJ, et al. Pilot trial of 1-octanol in essential tremor. Neurology 2004; 62: 122-124.
12. Shill HA, Bushara KO, Mari Z, et al. Open label dose escalation study of oral 1octanol in patients with essential tremor. Neurology 2004; 62: 2320-2322.
13. Nahab FB, Wittevrongel L, Ippolito D, et. al. An open-label, single-dose, crossover study of the pharmacokinetics and metabolism of two oral formulations of 1-octanol in patients with essential tremor. Neurotherapeutics 2011; 8: 753-762.
14. Haubenberger D, Kalowitz D, Nahab FB, et al. Validation of digital spiral analysis as outcome parameter for clinical trials in essential tremor. Mov Disord 2011; 26: 2073-2080.
15. Martin FC, Thu Le A, Handforth A. Harmaline-induced tremor as a potential preclinical screening method for essential tremor medications. Mov Disord 2005; 20: 298-305.
16. A receptor: differential interaction of benzodiazepines and neuroactive steroids with ethanol. Psychopharmacology (Berl) 1999; 141: 77-82.